Skip to main content
NVDA-1.22%AAPL+0.52%GOOGL-2.28%MSFT-0.62%AMZN-0.71%TSM-0.83%SPCX-3.86%AVGO-1.13%META-0.68%TSLA-1.98%SKHY+7.05%MU-2.78%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.59%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-2.40%0005.HK-0.78%HSBA.L-1.76%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.45%AUDJPY-1.72%CHFJPY-1.69%NZDCAD-1.37%NZDUSD-1.36%GBPJPY-1.29%EURJPY-1.28%EURNZD+1.21%GBPNZD+1.17%USDJPY-1.12%CADJPY-1.10%USDZAR+0.93%USDSEK+0.90%USDNOK+0.88%NZDCHF-0.79%AUDNZD+0.76%USDTHB+0.66%AUDCAD-0.65%AUDUSD-0.61%USDPLN+0.60%EURZAR+0.59%USDCHF+0.59%CADCHF+0.58%EURSEK+0.55%EURNOK+0.54%USDMXN+0.53%GBPZAR+0.52%AUDSGD-0.52%AUDDKK-0.47%EURAUD+0.45%GBPAUD+0.42%GBPTRY+0.41%EURCHF+0.40%GBPCHF+0.39%CHFSEK+0.36%EURHKD-0.36%CHFNOK+0.35%USDDKK+0.34%NZDSGD-0.34%SGDJPY+0.33%GBPHKD+0.32%USDSGD+0.29%GBPMXN-0.28%NOKJPY-0.26%EURPLN+0.26%CHFSGD-0.24%EURCNH-0.23%GBPCAD-0.21%EURCAD-0.19%EURUSD-0.17%GBPUSD-0.17%USDILS+0.16%NZDMXN-0.12%GBPSGD-0.12%USDTRY+0.11%USDCNH+0.09%AUDNOK+0.07%EURSGD-0.05%USDCOP-0.04%AUDCHF-0.03%EURGBP+0.02%PLNJPY+0.02%EURCZK-0.01%USDCAD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.99%XAGUSD-4.94%GAGUSD-4.91%HG1-4.38%USOIL+3.84%UKOIL+3.77%COFFEE-1.97%GAUUSD-1.74%XAUUSD-1.72%SUGAR+0.87%S1+0.86%C1+0.66%BTCUSD-1.53%ETHUSD-1.38%USDTUSD-0.04%XRPUSD-1.99%SOLUSD-1.56%TRXUSDT+0.15%ZECUSDT-2.42%DOGEUSD-1.93%XMRUSDT-1.84%LINKUSD-0.96%XLMUSD-1.67%BCHUSDT-3.83%LTCUSD-2.04%UNIUSD-2.80%TONUSD+24.88%HBARUSDT-2.07%SUIUSD-2.03%TAOUSDT-2.79%AAVEUSD-2.74%DOTUSDT-2.18%ICPUSDT-1.62%ONDOUSDT-2.73%WLDUSDT-1.47%ATOMUSDT-2.87%ARBUSDT-0.68%JUPUSDT-3.39%INJUSDT-2.47%STXUSDT-3.80%FETUSDT-3.18%TIAUSDT-1.13%PYTHUSDT-1.34%SEIUSDT-3.91%IMXUSDT-2.27%WIFUSDT-3.42%GRTUSDT-3.93%OPUSDT-1.99%POLUSDT-6.32%IOTAUSDT-3.86%AXSUSDT-2.47%FARTCOINUSDT-4.25%EOSUSDT-0.19%DYDXUSDT-0.49%ORDIUSDT-0.44%GALAUSDT-3.93%NOTUSDT-0.68%RONINUSDT-2.64%NVDA-1.22%AAPL+0.52%GOOGL-2.28%MSFT-0.62%AMZN-0.71%TSM-0.83%SPCX-3.86%AVGO-1.13%META-0.68%TSLA-1.98%SKHY+7.05%MU-2.78%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.59%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-2.40%0005.HK-0.78%HSBA.L-1.76%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.45%AUDJPY-1.72%CHFJPY-1.69%NZDCAD-1.37%NZDUSD-1.36%GBPJPY-1.29%EURJPY-1.28%EURNZD+1.21%GBPNZD+1.17%USDJPY-1.12%CADJPY-1.10%USDZAR+0.93%USDSEK+0.90%USDNOK+0.88%NZDCHF-0.79%AUDNZD+0.76%USDTHB+0.66%AUDCAD-0.65%AUDUSD-0.61%USDPLN+0.60%EURZAR+0.59%USDCHF+0.59%CADCHF+0.58%EURSEK+0.55%EURNOK+0.54%USDMXN+0.53%GBPZAR+0.52%AUDSGD-0.52%AUDDKK-0.47%EURAUD+0.45%GBPAUD+0.42%GBPTRY+0.41%EURCHF+0.40%GBPCHF+0.39%CHFSEK+0.36%EURHKD-0.36%CHFNOK+0.35%USDDKK+0.34%NZDSGD-0.34%SGDJPY+0.33%GBPHKD+0.32%USDSGD+0.29%GBPMXN-0.28%NOKJPY-0.26%EURPLN+0.26%CHFSGD-0.24%EURCNH-0.23%GBPCAD-0.21%EURCAD-0.19%EURUSD-0.17%GBPUSD-0.17%USDILS+0.16%NZDMXN-0.12%GBPSGD-0.12%USDTRY+0.11%USDCNH+0.09%AUDNOK+0.07%EURSGD-0.05%USDCOP-0.04%AUDCHF-0.03%EURGBP+0.02%PLNJPY+0.02%EURCZK-0.01%USDCAD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.99%XAGUSD-4.94%GAGUSD-4.91%HG1-4.38%USOIL+3.84%UKOIL+3.77%COFFEE-1.97%GAUUSD-1.74%XAUUSD-1.72%SUGAR+0.87%S1+0.86%C1+0.66%BTCUSD-1.53%ETHUSD-1.38%USDTUSD-0.04%XRPUSD-1.99%SOLUSD-1.56%TRXUSDT+0.15%ZECUSDT-2.42%DOGEUSD-1.93%XMRUSDT-1.84%LINKUSD-0.96%XLMUSD-1.67%BCHUSDT-3.83%LTCUSD-2.04%UNIUSD-2.80%TONUSD+24.88%HBARUSDT-2.07%SUIUSD-2.03%TAOUSDT-2.79%AAVEUSD-2.74%DOTUSDT-2.18%ICPUSDT-1.62%ONDOUSDT-2.73%WLDUSDT-1.47%ATOMUSDT-2.87%ARBUSDT-0.68%JUPUSDT-3.39%INJUSDT-2.47%STXUSDT-3.80%FETUSDT-3.18%TIAUSDT-1.13%PYTHUSDT-1.34%SEIUSDT-3.91%IMXUSDT-2.27%WIFUSDT-3.42%GRTUSDT-3.93%OPUSDT-1.99%POLUSDT-6.32%IOTAUSDT-3.86%AXSUSDT-2.47%FARTCOINUSDT-4.25%EOSUSDT-0.19%DYDXUSDT-0.49%ORDIUSDT-0.44%GALAUSDT-3.93%NOTUSDT-0.68%RONINUSDT-2.64%
AP

Aurinia Pharmaceuticals Inc. (AUPH)

NASDAQ • Healthcare

$16.25
+$0.17 (+1.1%)
Market closed

Last close at September 9, 2026 at 20:00 UTC

Open$15.97
Day Range$15.85 - $16.32
Avg. Volume (3M)984K
Market Cap$2B
P/E Ratio6.9
52 Week Range
$10.34$19.25
Next EarningsIn 54 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$83.2M100%
Gross Profitminus cost of goods$76.6M92%
Operating Incomeminus R&D and overhead$46.3M56%
Net Incomeminus taxes and the rest$37.4M45%

In plain terms: out of every $100 in revenue, Aurinia Pharmaceuticals Inc. keeps $45 as net profit.

Fundamentals & Financials

Revenue (TTM)
$311.5M
Net Income (TTM)
$314.1M
EPS (TTM)
$2.36
ROA (TTM)
39.65%
Current Ratio
5.42

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+23.8%Q1 2026$0.26
+38.9%Q2 2026$0.25
+16.7%Q3 2026$0.28
Next

Nov 3

in 54 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +16.7%

Aurinia Pharmaceuticals beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported August 6, with revenue rising 18.9% year over year to about $83.2 million (up from $70.0 million a year ago) while EPS of $0.28 topped the $0.24 estimate, +16.7%. Revenue of $83.2 million also topped the $80.4 million consensus, +3.4%, and profitability stayed high with gross margin near 92% and operating margin around 56%, alongside operating income of roughly $46.3 million. Net income increased 73.9% to about $37.4 million versus $21.5 million a year ago, and the quarter generated operating cash flow of approximately $52.2 million. Next-period consensus calls for EPS of $0.19 on revenue of $83.6 million.

View full earnings history

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is a biotechnology company that develops and commercializes therapies for diseases with inadequate current treatment options. Its business is centered on LUPKYNIS, an approved treatment for active lupus nephritis in adults, and it generated $283.1 million of revenue in FY2025.

Name
Aurinia Pharmaceuticals Inc.
CEO
Kevin C. Tang
Website
www.auriniapharma.com
Industry
Healthcare
Employees
128

Today's Snapshot

AI-generated

AUPH ended yesterday 1.1% up at 16.25.

Trading Volume

Below 10d avg (768.6K)

723.2K

vs S&P 500 Today

Outperforming Market

+1.60%

Updated: September 10, 2026 at 12:17 UTC

Technical Indicators

5 Buy3 Neutral0 Sell
AUPH displays a strong buy profile driven by broad-based confirmation from short, medium and long-term moving averages, which the price currently sits above, indicating uniform technical support. Momentum is mixed but near neutral while MACD is mildly positive, and ADX suggests moderate trend presence without excess volatility; ATR is subdued. On-balance volume is not supportive, presenting a divergence versus the bullish moving-average alignment, and pivot levels are close to the current price. Technical takeaway: Strong Buy — across-the-board moving-average support with moderate trend strength.
All signals
  • EMA (5 indicators)$15.17 - $16.18
    Buy
  • RSI (14)53.46
    Neutral
  • Stochastic %K (14, 3, 3)28.43
    Neutral
  • MACD Level (12, 26)0.13
    Neutral

Peers & Related Assets

CLDXCelldex Therapeutics, Inc.
$38.78-0.9%
VERAVera Therapeutics, Inc.
$33.78-4.3%
HRMYHarmony Biosciences Holdings, Inc.
$41.62-1.1%
NUVBNuvation Bio Inc.
$6.52-1.4%
BHVNBiohaven Ltd.
$15+1.9%
STOKStoke Therapeutics, Inc.
$29.92-0.4%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.